2. Search Result
Search Result
Isoforms Recommended: MT2
Results for "

MT-2

" in MedChemExpress (MCE) Product Catalog:

43

Inhibitors & Agonists

4

Natural
Products

7

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101358
    8-M-PDOT

    AH-002

    		 Melatonin Receptor Neurological Disease
    8-M-PDOT (AH-002) is a selective melatonin MT2 receptor agonist. 8-M-PDOT is 5.2-fold selective for MT2 over MT1 receptors. 8-M-PDOT binds human recombinant MT2 and MT2 receptors with pKi values of 8.23 and 8.95 respectively. 8-M-PDOT has anxiolytic-like activity [2].
    8-M-PDOT
  • HY-122136
    S26131
    5+ Cited Publications

    		 Melatonin Receptor Neurological Disease
    S26131 (compound 5) is a potent and selective MT1 melatoninergic ligand, and the Ki values are 0.5 and 112 nM for MT1 and MT2, respectively. S26131 behaves as an MT1 and MT2 antagonist .
    S26131
  • HY-101254
    Luzindole
    Maximum Cited Publications
    12 Publications Verification

    N-0774

    		 Melatonin Receptor Neurological Disease
    Luzindole (N-0774) is a selective melatonin receptor antagonist. Luzindole preferentially targets MT2 (Mel1b) over MT1 (Mel1a) with Ki values of 10.2 and 158 nM for human MT2 and MT1, respectively. Luzindole suppresses experimental autoimmune encephalomyelitis (EAE), and exerts antidepressant-like activity [2] .
    Luzindole
  • HY-17038S
    Agomelatine-d6

    S-20098-d6

    		 Isotope-Labeled Compounds Melatonin Receptor 5-HT Receptor Neurological Disease
    Agomelatine-d6 is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors[1] .
    Agomelatine-d6
  • HY-RS08743
    MT2A Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MT2A Human Pre-designed siRNA Set A contains three designed siRNAs for MT2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MT2A Human Pre-designed siRNA Set A
    MT2A Human Pre-designed siRNA Set A
  • HY-107628
    N-Pentanoyl 2-benzyltryptamine

    		Melatonin Receptor Neurological Disease
    N-Pentanoyl 2-benzyltryptamine is a potent and selective antagonist of MT2 melatonin receptor, with a pKi of 8.03 for human MT2. N-Pentanoyl 2-benzyltryptamine shows 89- and 229-fold selectivity for human MT2 over human mt1 and Xenopus mel1c receptor subtypes. N-Pentanoyl 2-benzyltryptamine can inhibit melatonin-induced enhancement of electrically-evoked responses [2].
    N-Pentanoyl 2-benzyltryptamine
  • HY-119010
    UCM 549

    		Melatonin Receptor Neurological Disease
    UCM 549 is a melatonin MT2 receptor inverse agonist and a MT1 receptor antagonist .
    UCM 549
  • HY-150079
    HIV-1 integrase inhibitor 10

    		HIV Integrase Infection
    HIV-1 integrase inhibitor 10 is an orally active HIV-1 allosteric integrase inhibitor (ALLINI). HIV-1 integrase inhibitor 10 can inhibit viral outgrowth of the NLRepRluc virus in MT-2 cells with EC50 values of 3-5 nM. HIV-1 integrase inhibitor 10 can be used for the research of Human immunodeficiency virus-1 (HIV-1) .
    HIV-1 integrase inhibitor 10
  • HY-159828
    Dezecapavir

    		Others Infection
    Dezecapavir (example 4) is a potent inhibitor of viral replication, with the EC50 of 0.025 nM and CC50 of ＞0.5 μM in MT2 cells .
    Dezecapavir
  • HY-147542
    Melatonin receptor agonist 1

    		Melatonin Receptor Neurological Disease
    Melatonin receptor agonist 1 (compound 20c) is a potent melatonin receptor (MT) agonist, with Ki values of 108 nM (MT2) and 1140 nM (MT1) .
    Melatonin receptor agonist 1
  • HY-101074
    UCM 608

    2-Phenylmelatonin

    		 Melatonin Receptor Neurological Disease Inflammation/Immunology Cancer
    UCM 608 is a high affinity melatonin (MT) membrane receptor agonist. The pKi values for MT1 and MT2 are 10.7 and 10.4 [2].
    UCM 608
  • HY-100609
    4-P-PDOT
    5+ Cited Publications

    		 Melatonin Receptor Neurological Disease
    4-P-PDOT is a potent, selective and affinity Melatonin receptor (MT2) antagonist. 4-P-PDOT is >300-fold more selective for MT2 than MT1. 4-P-PDOT significantly counteracts Melatonin-mediated antioxidant effects (GSH/GSSG ratio, phospho-ERK, Nrf2 nuclear translocation, Nrf2 DNA-binding activity) [2] .
    4-P-PDOT
  • HY-138626
    ACH-000143

    		Melatonin Receptor Metabolic Disease
    ACH-000143 is a potent and orally active melatonin receptor agonist, with EC50 values of 0.06 nM and 0.32 nM for MT1 and MT2, respectively .
    ACH-000143
  • HY-103005
    Ramelteon metabolite M-II

    		Melatonin Receptor Drug Metabolite Neurological Disease Endocrinology
    Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist.
    Ramelteon metabolite M-II
  • HY-133113
    7-Desmethyl-agomelatine
    1 Publications Verification

    		 5-HT Receptor Neurological Disease
    7-Desmethyl-agomelatine is a metabolite of Agomelatine. Agomelatineis a potent agonist at melatonin receptors (MT1 and MT2), and also is an antagonist of 5-HT2C [2].
    7-Desmethyl-agomelatine
  • HY-A0014
    Ramelteon
    5+ Cited Publications

    TAK-375

    		 Melatonin Receptor Neurological Disease Endocrinology Cancer
    Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation [2].
    Ramelteon
  • HY-B0439S1
    Sulfadoxine D3

    Sulphadoxine d3

    		 Parasite Antibiotic Infection
    Sulfadoxine-d3 is a deuterium labeled Sulfadoxine (HY-B0439). Sulfadoxine is a sulfonamide that is used, usually in combination with Pyrimethamine (HY-18062), for multidrug-resistant Plasmodium falciparum and P. vivax inhibition. Unlike PYR, Sulfadoxine has no impact on HIV replication or MT-2 cell cycle progression. But also Sulfadoxine exhibits suppression on respiratory, and urinary tract infections[1][2][3][4].
    Sulfadoxine D3
  • HY-A0014S
    Ramelteon-d5

    TAK-375-d5

    		 Isotope-Labeled Compounds Melatonin Receptor Neurological Disease Endocrinology Cancer
    Ramelteon-d5 is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation[1][2].
    Ramelteon-d5
  • HY-A0014R
    Ramelteon (Standard)

    		Melatonin Receptor Neurological Disease Endocrinology Cancer
    Ramelteon (Standard) is the analytical standard of Ramelteon. This product is intended for research and analytical applications. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation [2].
    Ramelteon (Standard)
  • HY-115861
    UCM765

    		Others Neurological Disease
    UCM765 is a selective MT2-type melatonin receptor ligand with hypnotic, analgesic and anxiolytic activities. The partial agonist effect of UCM765 has attracted attention in pharmacological studies. By structurally modifying UCM765, its water solubility and metabolic stability can be improved, thereby increasing its bioavailability. The biological activity of UCM765 has been verified in a rat model, supporting its potential for further pharmacological studies .
    UCM765
  • HY-133112
    7-Desmethyl-3-hydroxyagomelatine

    3-Hydroxy-7-desmethyl agomelatine

    		 Melatonin Receptor 5-HT Receptor Neurological Disease
    7-Desmethyl-3-hydroxyagomelatine (3-Hydroxy-7-desmethyl agomelatine), a metabolite of Agomelatine, has less activity than Agomelatine . Agomelatine is a melatonergic (MT1 and MT2) agonist and serotonergic (5HT2C) antagonist [2].
    7-Desmethyl-3-hydroxyagomelatine
  • HY-101176
    2-Iodomelatonin
    2 Publications Verification

    		 Melatonin Receptor Cancer
    2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a Ki value of 28 pM, it is more 5-fold selective for MT1  over MT2 . 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues .
    2-Iodomelatonin
  • HY-103005S
    Ramelteon metabolite M-II-d3

    		Melatonin Receptor Drug Metabolite Neurological Disease Endocrinology
    Ramelteon metabolite M-II-d3 is the deuterium labeled Ramelteon metabolite M-II. Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist[1][2].
    Ramelteon metabolite M-II-d3
  • HY-14803
    Tasimelteon

    BMS-214778; VEC-162

    		 Melatonin Receptor Neurological Disease Endocrinology
    Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24) [2].
    Tasimelteon
  • HY-105285
    Piromelatine

    Neu-P11

    		 Melatonin Receptor 5-HT Receptor P2X Receptor TRP Channel Sodium Channel Neurological Disease
    Piromelatine (Neu-P11) is a melatonin MT1/MT2 receptor agonist, serotonin 5-HT1A/5-HT1D agonist, and serotonin 5-HT2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities [2] .
    Piromelatine
  • HY-14803S
    Tasimelteon-d5

    BMS-214778-d5; VEC-162-d5

    		 Isotope-Labeled Compounds Melatonin Receptor Neurological Disease Endocrinology
    Tasimelteon-d5 is the deuterium labeled Tasimelteon. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2].
    Tasimelteon-d5
  • HY-100940
    6-Chloromelatonin

    		Melatonin Receptor Endocrinology
    6-Chloromelatonin is a potent melatonin receptor agonist with greater metabolic stability than melatonin. 6-Chloromelatonin compete for [ 3H]-melatonin and 2-[ 125I]-iodomelatonin binding to MT1 receptors (pKi=8.9 and 9.1, respectively). 6-Chloromelatonin compete for [ 3H]-melatonin binding to MT2 receptors (pKi=9.77) [2].
    6-Chloromelatonin
  • HY-114962
    S-22153

    		Melatonin Receptor Neurological Disease
    S-22153 is a potent melatonin receptor antagonist with EC50 values of 19 nM, 4.6 nM for hMT1 and hMT2 melatonin receptor, respectively. S-22153 has Ki values of 8.6 nM (CHO cells) and 16.3 nM (HEK cells) for hMT1, and 6.0 nM (CHO cells) and 8.2 nM (HEK cells) for hMT2. S-22153 is a specific ligand of MT1 and MT2 melatonin receptors subtypes [2].
    S-22153
  • HY-14803R
    Tasimelteon (Standard)

    		Melatonin Receptor Neurological Disease Endocrinology
    Tasimelteon (Standard) is the analytical standard of Tasimelteon. This product is intended for research and analytical applications. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24) [2].
    Tasimelteon (Standard)
  • HY-106136
    TIK-301

    PD-6735; LY-156735

    		 Melatonin Receptor 5-HT Receptor Neurological Disease
    TIK-301 (PD-6735) is a chlorinated melatonin derivative and a potent, high-affinity and orally active melatonin MT1 and MT2 receptors agonist with Kis of 0.081 nM and 0.042 nM, respectively. TIK-301 is also a 5-HT2B/5-HT2C receptors antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment [2] .
    TIK-301
  • HY-17038
    Agomelatine
    4 Publications Verification

    S-20098

    		 Melatonin Receptor 5-HT Receptor Endogenous Metabolite Neurological Disease
    Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively [2].
    Agomelatine
  • HY-17038A
    Agomelatine hydrochloride
    4 Publications Verification

    S-20098 hydrochloride

    		 Melatonin Receptor 5-HT Receptor Endogenous Metabolite Neurological Disease
    Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively [2].
    Agomelatine hydrochloride
  • HY-17038B
    Agomelatine (L(+)-Tartaric acid)
    4 Publications Verification

    S-20098 L(+)-Tartaric acid

    		 Melatonin Receptor 5-HT Receptor Endogenous Metabolite Neurological Disease
    Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively [2].
    Agomelatine (L(+)-Tartaric acid)
  • HY-17038S1
    Agomelatine-d4

    S-20098-d4

    		 Isotope-Labeled Compounds Melatonin Receptor 5-HT Receptor Endogenous Metabolite Neurological Disease
    Agomelatine-d4 is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].
    Agomelatine-d4
  • HY-17038S2
    Agomelatin-d3

    S-20098-d3

    		 Melatonin Receptor 5-HT Receptor Endogenous Metabolite Neurological Disease
    Agomelatin-d3 is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].
    Agomelatin-d3
  • HY-17038R
    Agomelatine (Standard)

    		Melatonin Receptor 5-HT Receptor Endogenous Metabolite Neurological Disease
    Agomelatine (Standard) is the analytical standard of Agomelatine. This product is intended for research and analytical applications. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively [2].
    Agomelatine (Standard)
  • HY-139090
    3-Oxobetulin acetate

    28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin

    		 Others Infection
    3-Oxobetulin acetate is a derivative of the cholesterol biosynthesis inhibitor Betulin (HY-N0083). It inhibits the growth of P388 murine lymphocytic leukemia cells (EC50=0.12 μg/mL), as well as human MCF-7 breast, SF-268 CNS, H460 lung, and KM20L2 colon cancer cells (GI50s=8, 10.6, 5.2, and 12.7 μg/mL, respectively), but not BxPC-3 pancreas or DU145 prostate cancer cells (GI50s=>10 μg/mL for both).2 3-Oxobetulin acetate inhibits replication of X4 tropic recombinant HIV (NL4.3-Ren) in MT-2 lymphoblastoid cells (IC50=13.4 μM). It is also active against L. donovani amastigotes when used at a concentration of 50 μM.
    3-Oxobetulin acetate
  • HY-153782
    GSK878

    		HIV Infection
    GSK878 is a highly potent, long-acting HIV-1 inhibitor with the EC50 of 39 pM .
    GSK878
  • HY-162525
    GS-9770

    		HIV Protease Infection
    GS-9770 is an orally active inhibitor for HIV protease with Ki of 0.16 nM. GS-9770 exhibits antiviral activity aginst HIV-1 strains and HIV-2 strains with EC50 of 1.9-26 nM, and 26 nM. GS-9770 is metabolic stable in human liver microsomes. GS-9770 exhibits good pharmacokinetic characters in Sprague Dawley rats .
    GS-9770
  • HY-122018
    GS-9148

    		HIV Reverse Transcriptase Infection
    GS-9148 is a ribose-modified HIV-1 nucleotide reverse transcriptase (RT) inhibitor with an EC50 value of 10.6 µM. GS-9148 shows antiretroviral activity for K65R, L74V, or M184V RT mutation .
    GS-9148
  • HY-139985
    NBD-14189

    		HIV Infection
    NBD-14189 is a potent HIV-1 entry antagonist with an IC50 of 89 nM against the HIV-1HXB2 pseudovirus. NBD-14189 binds to HIV-1 gp120 and shows potent antiviral activity (EC50<200 nM) [2].
    NBD-14189
  • HY-17605A
    Bictegravir sodium
    10+ Cited Publications

    GS-9883 sodium

    		 HIV Integrase HIV Infection
    Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity .
    Bictegravir sodium
  • HY-120075
    TJ191

    		Apoptosis Cancer
    TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research .
    TJ191

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: